Published in Cancer Biol Ther on July 26, 2010
Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity. Sci Transl Med (2013) 1.69
Dissecting the Dual Role of AMPK in Cancer: From Experimental to Human Studies. Mol Cancer Res (2015) 0.97
AMPK Phosphorylation Modulates Pain by Activation of NLRP3 Inflammasome. Antioxid Redox Signal (2015) 0.85
Is 5´-AMP-Activated Protein Kinase Both Jekyll and Hyde in Bladder Cancer? Int Neurourol J (2015) 0.85
The rational design of a novel potent analogue of the 5'-AMP-activated protein kinase inhibitor compound C with improved selectivity and cellular activity. Bioorg Med Chem Lett (2010) 0.78
Deoxypodophyllotoxin suppresses tumor vasculature in HUVECs by promoting cytoskeleton remodeling through LKB1-AMPK dependent Rho A activatio. Oncotarget (2015) 0.77
Past strategies and future directions for identifying AMP-activated protein kinase (AMPK) modulators. Pharmacol Ther (2014) 0.76
Close encounters of a novel kind: a multi-targeted cancer drug meets a metabolic sensor. Cancer Biol Ther (2010) 0.75
Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest (2001) 23.21
The selectivity of protein kinase inhibitors: a further update. Biochem J (2007) 15.73
A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol (2008) 14.74
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res (2003) 9.92
Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer (2009) 9.26
The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer (2009) 8.43
Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab (2005) 8.30
Ca2+/calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells. Cell Metab (2005) 7.15
The Ca2+/calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases. J Biol Chem (2005) 6.27
Error bars in experimental biology. J Cell Biol (2007) 5.81
A role for AMP-activated protein kinase in contraction- and hypoxia-regulated glucose transport in skeletal muscle. Mol Cell (2001) 5.57
Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol (2006) 5.03
Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer (2008) 4.43
5'-AMP-activated protein kinase (AMPK) is induced by low-oxygen and glucose deprivation conditions found in solid-tumor microenvironments. Mol Cell Biol (2006) 4.28
Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov (2007) 4.27
Similar substrate recognition motifs for mammalian AMP-activated protein kinase, higher plant HMG-CoA reductase kinase-A, yeast SNF1, and mammalian calmodulin-dependent protein kinase I. FEBS Lett (1995) 3.42
LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. Acta Physiol (Oxf) (2009) 2.94
KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci U S A (2009) 2.84
Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer. Biochim Biophys Acta (2009) 2.70
Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinase. Biochem Soc Trans (2002) 2.47
Hypoxia signals autophagy in tumor cells via AMPK activity, independent of HIF-1, BNIP3, and BNIP3L. Cell Death Differ (2008) 2.45
Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun (2007) 2.36
A general strategy for creating "inactive-conformation" abl inhibitors. Chem Biol (2006) 2.27
AMPK: a metabolic gauge regulating whole-body energy homeostasis. Trends Mol Med (2008) 2.16
Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. Mol Cancer Res (2006) 2.06
Regulation of AMP-activated protein kinase by multisite phosphorylation in response to agents that elevate cellular cAMP. J Biol Chem (2006) 1.93
Regulation of 5'-AMP-activated protein kinase activity by the noncatalytic beta and gamma subunits. J Biol Chem (1996) 1.93
The generalized Born/volume integral implicit solvent model: estimation of the free energy of hydration using London dispersion instead of atomic surface area. J Comput Chem (2008) 1.90
AMP-activated protein kinase promotes human prostate cancer cell growth and survival. Mol Cancer Ther (2009) 1.48
The regulation and function of mammalian AMPK-related kinases. Acta Physiol (Oxf) (2009) 1.29
Optimization of a pyrazolo[1,5-a]pyrimidine class of KDR kinase inhibitors: improvements in physical properties enhance cellular activity and pharmacokinetics. Bioorg Med Chem Lett (2002) 1.23
Sunitinib in solid tumors. Expert Opin Investig Drugs (2009) 1.20
Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer. Oncologist (2007) 1.14
Mechanisms of myocyte cytotoxicity induced by the multiple receptor tyrosine kinase inhibitor sunitinib. Mol Pharmacol (2008) 1.12
Energy homeostasis and cancer prevention: the AMP-activated protein kinase. Cancer Prev Res (Phila) (2009) 1.07
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors. J Steroid Biochem Mol Biol (2007) 0.90
Scoring of KDR kinase inhibitors: using interaction energy as a guide for ranking. Mol Divers (2006) 0.78
5'-AMP-activated protein kinase (AMPK) is induced by low-oxygen and glucose deprivation conditions found in solid-tumor microenvironments. Mol Cell Biol (2006) 4.28
Double belt structure of discoidal high density lipoproteins: molecular basis for size heterogeneity. J Mol Biol (2004) 1.36
The response of c-jun/AP-1 to chronic hypoxia is hypoxia-inducible factor 1 alpha dependent. Mol Cell Biol (2002) 1.12
Activity of piperaquine and other 4-aminoquinoline antiplasmodial drugs against chloroquine-sensitive and resistant blood-stages of Plasmodium falciparum. Role of beta-haematin inhibition and drug concentration in vacuolar water- and lipid-phases. Biochem Pharmacol (2007) 1.10
5'-AMP-activated protein kinase activity is elevated early during primary brain tumor development in the rat. Int J Cancer (2011) 1.04
Synthesis and testing of a focused phenothiazine library for binding to HIV-1 TAR RNA. Chem Biol (2006) 1.01
Small molecule chemokine mimetics suggest a molecular basis for the observation that CXCL10 and CXCL11 are allosteric ligands of CXCR3. Br J Pharmacol (2012) 0.99
Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models. J Med Chem (2010) 0.98
Parallel synthesis of 9-aminoacridines and their evaluation against chloroquine-resistant Plasmodium falciparum. Bioorg Med Chem (2005) 0.95
Enrichment of extremely noisy high-throughput screening data using a naïve Bayes classifier. J Biomol Screen (2004) 0.94
Glucose utilization is essential for hypoxia-inducible factor 1 alpha-dependent phosphorylation of c-Jun. Mol Cell Biol (2004) 0.93
Acylideneoxoindoles: a new class of reversible inhibitors of human transglutaminase 2. Bioorg Med Chem Lett (2010) 0.92
Structure-activity relationship study of 9-aminoacridine compounds in scrapie-infected neuroblastoma cells. Bioorg Med Chem Lett (2006) 0.88
A high-throughput fluorescence polarization assay for inhibitors of gyrase B. J Biomol Screen (2011) 0.84
A novel steroidal inhibitor of estrogen-related receptor alpha (ERR alpha). Biochem Pharmacol (2010) 0.84
Evaluation of gyrase B as a drug target in Mycobacterium tuberculosis. J Antimicrob Chemother (2011) 0.83
Technique for generating three-dimensional alignments of multiple ligands from one-dimensional alignments. J Chem Inf Model (2008) 0.81
How can we improve antibody-based cancer therapy? MAbs (2010) 0.80
Discovery and optimization of benzotriazine di-N-oxides targeting replicating and nonreplicating Mycobacterium tuberculosis. J Med Chem (2012) 0.79
Mannich reaction derivatives of novobiocin with modulated physiochemical properties and their antibacterial activities. Bioorg Med Chem Lett (2011) 0.79
The rational design of a novel potent analogue of the 5'-AMP-activated protein kinase inhibitor compound C with improved selectivity and cellular activity. Bioorg Med Chem Lett (2010) 0.78
Bulged DNA substrates for identifying poxvirus resolvase inhibitors. Nucleic Acids Res (2012) 0.77
Freely available software programs for drug discovery. Curr Top Med Chem (2012) 0.75
Transplant-insert-constrain-relax-assemble (TICRA): protein-ligand complex structure modeling and application to kinases. J Chem Inf Model (2010) 0.75
Computational approach to de novo discovery of fragment binding for novel protein states. Methods Enzymol (2011) 0.75